Broadening specificity and enhancing cytotoxicity of adoptive T cells for nasopharyngeal carcinoma immunotherapy

Damiana Antonia Fae, Debora Martorelli, Katy Mastorci, Elena Muraro, Jessica Dal Col, Giovanni Franchin, Luigi Barzan, Elisa Comaro, Emanuela Vaccher, Antonio Rosato, Riccardo Dolcetti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although promising, clinical responses to adoptive immunotherapy for nasopharyngeal carcinoma (NPC) are still limited by the restricted number of Epstein-Barr virus (EBV) antigens that can be targeted and their poor immunogenicity. Our previous work indicated that the immunogenic features of the NPCassociated viral antigen BARF1 may be exploited for immunotherapeutic purposes. Nevertheless, T-cell lines obtained with current protocols include only negligible numbers of BARF1-specific cytotoxic T lymphocytes, pointing to the need to enrich these effectors in BARF1 specificities. Considering that in B lymphocytes BARF1 is mainly a lytic EBV antigen, we tested different EBV lytic-cycle inducers (TPA/butyric acid, doxorubicin, and cisplatin) used at suboptimal concentrations for their ability to upregulate BARF1 expression in lymphoblastoid B-cell lines (LCL), the commonly used antigen-presenting cells, without compromising their survival. The LCLs treated with doxorubicin (DX-LCL) can reproducibly and efficiently generate EBV-specific effectors enriched in BARF1 specificities from both healthy donors and NPC patients. These DX-LCLs also had more pronounced immunogenic properties, including HLA class I upregulation and expression of immunogenic cell death markers, such as enhanced calreticulin exposure and HMGB1 release. In particular, doxorubicin triggers an HMGB1 autocrine/ paracrine loop with its receptor, TLR4, which is also upregulated in DX-LCLs and is responsible for NF-kB activation and a delayed apoptosis that allows a prolonged stimulation of EBV-specific T-cell precursors. This protocol may thus constitute a valid alternative to the use of engineered LCLs to generate EBV-specific T-cell lines for adoptive immunotherapy, being relatively simple, easily upgradable to Good Manufacturing Practice standards, and therefore more broadly applicable.

Original languageEnglish
Pages (from-to)431-440
Number of pages10
JournalCancer immunology research
Volume4
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Human Herpesvirus 4
Immunotherapy
T-Lymphocytes
Doxorubicin
HMGB1 Protein
Adoptive Immunotherapy
Cell Line
B-Lymphocytes
Up-Regulation
T-Lymphoid Precursor Cells
Calreticulin
Antigens
Toll-Like Receptor 4
Butyric Acid
Viral Antigens
NF-kappa B
Cytotoxic T-Lymphocytes
Antigen-Presenting Cells
Cisplatin
Nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

Broadening specificity and enhancing cytotoxicity of adoptive T cells for nasopharyngeal carcinoma immunotherapy. / Fae, Damiana Antonia; Martorelli, Debora; Mastorci, Katy; Muraro, Elena; Col, Jessica Dal; Franchin, Giovanni; Barzan, Luigi; Comaro, Elisa; Vaccher, Emanuela; Rosato, Antonio; Dolcetti, Riccardo.

In: Cancer immunology research, Vol. 4, No. 5, 01.05.2016, p. 431-440.

Research output: Contribution to journalArticle

@article{c17aa0a4a4c540d09f6116102a7f933b,
title = "Broadening specificity and enhancing cytotoxicity of adoptive T cells for nasopharyngeal carcinoma immunotherapy",
abstract = "Although promising, clinical responses to adoptive immunotherapy for nasopharyngeal carcinoma (NPC) are still limited by the restricted number of Epstein-Barr virus (EBV) antigens that can be targeted and their poor immunogenicity. Our previous work indicated that the immunogenic features of the NPCassociated viral antigen BARF1 may be exploited for immunotherapeutic purposes. Nevertheless, T-cell lines obtained with current protocols include only negligible numbers of BARF1-specific cytotoxic T lymphocytes, pointing to the need to enrich these effectors in BARF1 specificities. Considering that in B lymphocytes BARF1 is mainly a lytic EBV antigen, we tested different EBV lytic-cycle inducers (TPA/butyric acid, doxorubicin, and cisplatin) used at suboptimal concentrations for their ability to upregulate BARF1 expression in lymphoblastoid B-cell lines (LCL), the commonly used antigen-presenting cells, without compromising their survival. The LCLs treated with doxorubicin (DX-LCL) can reproducibly and efficiently generate EBV-specific effectors enriched in BARF1 specificities from both healthy donors and NPC patients. These DX-LCLs also had more pronounced immunogenic properties, including HLA class I upregulation and expression of immunogenic cell death markers, such as enhanced calreticulin exposure and HMGB1 release. In particular, doxorubicin triggers an HMGB1 autocrine/ paracrine loop with its receptor, TLR4, which is also upregulated in DX-LCLs and is responsible for NF-kB activation and a delayed apoptosis that allows a prolonged stimulation of EBV-specific T-cell precursors. This protocol may thus constitute a valid alternative to the use of engineered LCLs to generate EBV-specific T-cell lines for adoptive immunotherapy, being relatively simple, easily upgradable to Good Manufacturing Practice standards, and therefore more broadly applicable.",
author = "Fae, {Damiana Antonia} and Debora Martorelli and Katy Mastorci and Elena Muraro and Col, {Jessica Dal} and Giovanni Franchin and Luigi Barzan and Elisa Comaro and Emanuela Vaccher and Antonio Rosato and Riccardo Dolcetti",
year = "2016",
month = "5",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0108",
language = "English",
volume = "4",
pages = "431--440",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Broadening specificity and enhancing cytotoxicity of adoptive T cells for nasopharyngeal carcinoma immunotherapy

AU - Fae, Damiana Antonia

AU - Martorelli, Debora

AU - Mastorci, Katy

AU - Muraro, Elena

AU - Col, Jessica Dal

AU - Franchin, Giovanni

AU - Barzan, Luigi

AU - Comaro, Elisa

AU - Vaccher, Emanuela

AU - Rosato, Antonio

AU - Dolcetti, Riccardo

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Although promising, clinical responses to adoptive immunotherapy for nasopharyngeal carcinoma (NPC) are still limited by the restricted number of Epstein-Barr virus (EBV) antigens that can be targeted and their poor immunogenicity. Our previous work indicated that the immunogenic features of the NPCassociated viral antigen BARF1 may be exploited for immunotherapeutic purposes. Nevertheless, T-cell lines obtained with current protocols include only negligible numbers of BARF1-specific cytotoxic T lymphocytes, pointing to the need to enrich these effectors in BARF1 specificities. Considering that in B lymphocytes BARF1 is mainly a lytic EBV antigen, we tested different EBV lytic-cycle inducers (TPA/butyric acid, doxorubicin, and cisplatin) used at suboptimal concentrations for their ability to upregulate BARF1 expression in lymphoblastoid B-cell lines (LCL), the commonly used antigen-presenting cells, without compromising their survival. The LCLs treated with doxorubicin (DX-LCL) can reproducibly and efficiently generate EBV-specific effectors enriched in BARF1 specificities from both healthy donors and NPC patients. These DX-LCLs also had more pronounced immunogenic properties, including HLA class I upregulation and expression of immunogenic cell death markers, such as enhanced calreticulin exposure and HMGB1 release. In particular, doxorubicin triggers an HMGB1 autocrine/ paracrine loop with its receptor, TLR4, which is also upregulated in DX-LCLs and is responsible for NF-kB activation and a delayed apoptosis that allows a prolonged stimulation of EBV-specific T-cell precursors. This protocol may thus constitute a valid alternative to the use of engineered LCLs to generate EBV-specific T-cell lines for adoptive immunotherapy, being relatively simple, easily upgradable to Good Manufacturing Practice standards, and therefore more broadly applicable.

AB - Although promising, clinical responses to adoptive immunotherapy for nasopharyngeal carcinoma (NPC) are still limited by the restricted number of Epstein-Barr virus (EBV) antigens that can be targeted and their poor immunogenicity. Our previous work indicated that the immunogenic features of the NPCassociated viral antigen BARF1 may be exploited for immunotherapeutic purposes. Nevertheless, T-cell lines obtained with current protocols include only negligible numbers of BARF1-specific cytotoxic T lymphocytes, pointing to the need to enrich these effectors in BARF1 specificities. Considering that in B lymphocytes BARF1 is mainly a lytic EBV antigen, we tested different EBV lytic-cycle inducers (TPA/butyric acid, doxorubicin, and cisplatin) used at suboptimal concentrations for their ability to upregulate BARF1 expression in lymphoblastoid B-cell lines (LCL), the commonly used antigen-presenting cells, without compromising their survival. The LCLs treated with doxorubicin (DX-LCL) can reproducibly and efficiently generate EBV-specific effectors enriched in BARF1 specificities from both healthy donors and NPC patients. These DX-LCLs also had more pronounced immunogenic properties, including HLA class I upregulation and expression of immunogenic cell death markers, such as enhanced calreticulin exposure and HMGB1 release. In particular, doxorubicin triggers an HMGB1 autocrine/ paracrine loop with its receptor, TLR4, which is also upregulated in DX-LCLs and is responsible for NF-kB activation and a delayed apoptosis that allows a prolonged stimulation of EBV-specific T-cell precursors. This protocol may thus constitute a valid alternative to the use of engineered LCLs to generate EBV-specific T-cell lines for adoptive immunotherapy, being relatively simple, easily upgradable to Good Manufacturing Practice standards, and therefore more broadly applicable.

UR - http://www.scopus.com/inward/record.url?scp=84976565533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976565533&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0108

DO - 10.1158/2326-6066.CIR-15-0108

M3 - Article

VL - 4

SP - 431

EP - 440

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 5

ER -